The past six months have seen a growing conflict in the 340B Drug Pricing Program, much of which has been centered on the role of contract pharmacies, which have expanded rapidly in the past decade.

As manufacturers evaluate their options, some may be tempted to see these developments as a setback. However, engagement with contract pharmacies can also be seen as an opportunity — a chance to reset stakeholder relationships that have become unsustainably contentious.

In this whitepaper, you’ll learn:

• How relationships with contract pharmacies offer a chance to improve market access
• How to mitigate compliance risks associated with contract pharmacies
• Why collaboration is critical to successful Drug Discount Management

Download today to learn more.